SCHEDULE: Vanguard Discloses 5.2% Stake in Amicus Therapeutics

Vanguard Capital Management has reported beneficial ownership of 5.2% of Amicus Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 16,350,837 shares of Amicus Therapeutics Inc. common stock.
• This holding represents 5.2% of the total class of securities.
• The filing indicates sole voting power over 2,327,280 shares and sole dispositive power over all 16,350,837 shares.
• The reporting date for this ownership stake is March 31, 2026.
• Vanguard Capital Management is classified as an investment adviser and holds these securities in the ordinary course of business, not for the purpose of influencing control.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While Vanguard's investment is significant, the Schedule 13G filing indicates a passive investment strategy, not an endorsement or criticism of Amicus Therapeutics' specific operations or future prospects.

Positives

• Vanguard Capital Management, a significant institutional investor, has taken a notable stake in Amicus Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The filing confirms Vanguard's sole dispositive power over the shares, indicating direct control over investment decisions for these holdings.

Negatives

• The filing does not contain any negative financial results or operational setbacks for Amicus Therapeutics; it solely reports on Vanguard's ownership.

Risks

• The primary risk associated with this filing is the potential for significant share sales by Vanguard, which could negatively impact Amicus Therapeutics' stock price.
• As an institutional investor, Vanguard's investment strategy could shift, leading to a reduction or elimination of their stake, thereby affecting market sentiment.

Future Outlook

This filing is a snapshot of ownership as of March 31, 2026, and does not contain forward-looking statements or guidance from Amicus Therapeutics Inc. regarding its business operations or financial performance.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major asset manager like Vanguard indicates a passive investment approach, typically for index funds or diversified portfolios, rather than an activist stake. This suggests Vanguard views Amicus Therapeutics as a component within a broader investment strategy rather than a target for strategic influence.

Comparison to Industry Standards

• Vanguard's typical investment in companies like Amicus Therapeutics, especially when filing a Schedule 13G, aligns with the industry standard for large, diversified asset managers who manage index funds or broad market ETFs. These managers aim to track market indices and hold stakes in companies proportionally to their market capitalization.
• For instance, BlackRock, another major asset manager, also files Schedule 13G for similar passive holdings across numerous biotechnology companies, reflecting a common practice for institutional investors seeking broad market exposure without active control.
• The 5.2% ownership threshold is a common level for institutional investors to reach before potentially considering more active engagement or filing a Schedule 13D, but the 13G designation implies a passive intent.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's passive stake, which can add stability to the shareholder base but does not imply active support or opposition to management's strategies.
• Management: The filing indicates that Vanguard is not seeking to influence control, allowing Amicus Therapeutics' management to continue its strategic direction without immediate pressure from this specific investor.
• Creditors: A stable, large institutional shareholder can be viewed positively by creditors as it may indicate a more stable corporate environment.

Next Steps

• Vanguard Capital Management will continue to hold or adjust its stake in Amicus Therapeutics Inc. based on its investment strategies and market conditions.
• Amicus Therapeutics Inc. will continue its operations and business development activities, with Vanguard's passive ownership being a factor in its shareholder base.

Key Dates

Keywords

Amicus Therapeutics, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management